241 related articles for article (PubMed ID: 24835218)
41. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
[TBL] [Abstract][Full Text] [Related]
42. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
43. A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib.
Xing K; Zhou X; Zhao X; Sun S; Luo Z; Wang H; Yu H; Wang J; Chang J; Wu X; Hu A
Med Oncol; 2014 Jul; 31(7):36. PubMed ID: 24908064
[TBL] [Abstract][Full Text] [Related]
44. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Yang JC; Sequist LV; Zhou C; Schuler M; Geater SL; Mok T; Hu CP; Yamamoto N; Feng J; O'Byrne K; Lu S; Hirsh V; Huang Y; Sebastian M; Okamoto I; Dickgreber N; Shah R; Märten A; Massey D; Wind S; Wu YL
Ann Oncol; 2016 Nov; 27(11):2103-2110. PubMed ID: 27601237
[TBL] [Abstract][Full Text] [Related]
45. [Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].
Vidal ÓJ
Med Clin (Barc); 2016 Apr; 146 Suppl 1():12-8. PubMed ID: 27426243
[TBL] [Abstract][Full Text] [Related]
46. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Yang JC; Hirsh V; Schuler M; Yamamoto N; O'Byrne KJ; Mok TS; Zazulina V; Shahidi M; Lungershausen J; Massey D; Palmer M; Sequist LV
J Clin Oncol; 2013 Sep; 31(27):3342-50. PubMed ID: 23816967
[TBL] [Abstract][Full Text] [Related]
47. Long progression-free survival with afatinib in a patient with EGFR-unknown lung adenocarcinoma after erlotinib failure: a case report.
Vitale MG; Scagliarini S; Riccardi F; Barbato C; Otero M; Mocerino C; Ambrosio F; Cartenì G
Tumori; 2015 Apr; 101(2):e64-6. PubMed ID: 25702672
[TBL] [Abstract][Full Text] [Related]
48. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Lammers PE; Lovly CM; Horn L
J Natl Compr Canc Netw; 2014 Jan; 12(1):6-11; quiz 11. PubMed ID: 24453288
[TBL] [Abstract][Full Text] [Related]
49. Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
Liu J; Jin B; Su H; Qu X; Liu Y
BMC Cancer; 2019 Jul; 19(1):702. PubMed ID: 31315676
[TBL] [Abstract][Full Text] [Related]
50. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
51. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
Oh IJ; Hur JY; Park CK; Kim YC; Kim SJ; Lee MK; Kim HJ; Lee KY; Lee JC; Choi CM
Clin Lung Cancer; 2018 Sep; 19(5):e775-e781. PubMed ID: 30149884
[TBL] [Abstract][Full Text] [Related]
52. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Kozlov V; Karpov I; Kovalenko S; Shamanin V
Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
[TBL] [Abstract][Full Text] [Related]
53. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
54. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
Čoupková H; Vyzula R
Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
[TBL] [Abstract][Full Text] [Related]
55. Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Longo L; Mengoli MC; Bertolini F; Bettelli S; Manfredini S; Rossi G
Lung Cancer; 2017 Jan; 103():24-26. PubMed ID: 28024692
[TBL] [Abstract][Full Text] [Related]
56. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
Keating GM
Drugs; 2014 Feb; 74(2):207-21. PubMed ID: 24435321
[TBL] [Abstract][Full Text] [Related]
57. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
58. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
Engle JA; Kolesar JM
Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
[TBL] [Abstract][Full Text] [Related]
59. Prolonged Response to Afatinib and Crizotinib in a Rare Case of
Plomer E; Früh M; Lauber A; Demmer I; Jochum W; Koster KL
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891886
[TBL] [Abstract][Full Text] [Related]
60. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
